Research a compound stack end to end — a structured protocol scaffold, how VialTalk researchers actually combine these compounds, receptor conflicts, and live COA-verified prices. Add 1–5 compounds.
Research signals
Redundancy, true conflicts, and dangerous additive effects
Review advised
No documented conflicts — some notes to review
Receptor activity map
| Receptor | Retatrutide | BPC-157 |
|---|---|---|
| GLP-1 receptor (GLP-1R) | ||
| GIP receptor (GIPR) | ||
| Glucagon receptor (GCGR) | ||
| VEGFR2 pathway | ||
| Nitric oxide system | ||
| Dopaminergic pathways |
A structured, research-grounded protocol for this stack
Sign in to build a structured research protocol scaffold for BPC-157 + Retatrutide — phases, per-compound parameters, endpoints and washout, grounded in documented research.
What VialTalk researchers actually run
No researchers have logged this exact combination yet — yours could be the first.
Forum discussions on this stack
0 replies
0 replies
0 replies
3 replies
0 replies
Researchers are also adding
Best price for each compound today
Same “From” price shown on each compound's page (after discounts). Panels = COA assays tested. Tap “Compare all vendors” for the full breakdown.
For research and informational use only. VialTalk does not provide medical advice or dosing guidance. Community data reflects self-reported public research journals.